VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding
Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.
Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.
"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.
Two cohort studies showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.
No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.
"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."
Bictegravir-containing regimens performed well over 48 weeks, with more than 90% of participants achieving a viral load less than 50 copies/mL.
A recent clinical trial found that doravirine was roughly equivalent in potency to darunavir-based regimens.
At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.